Adjuvant Therapy for Renal Cell Carcinoma |
| |
| Affiliation: | 1. Department of Urology, Haeundae Paik Hospital, Inje University College of Medicine, Busan, South Korea;2. Department of Urology, Hallym University Sacred Heart Hospital, Hallym University College of Medicine, Anyang, GyeongGi-Do, South Korea;3. Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea;1. Service de chirurgie générale et thoracique, CHU de Rouen, 1, rue de Germont, 76000 Rouen, France;2. Service de chirurgie thoracique, des maladies de l’œsophage et de transplantations pulmonaires, hôpital Nord, Aix Marseille université, Assistance publique–Hôpitaux de Marseille, chemin des Bourrely, 13915 Marseille, France;1. Comprehensive Cancer Center – Musculoskeletal Tumors, Medical University of Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria;2. Department of Internal Medicine I/Oncology, Medical University of Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria;3. Department of Thoracic Surgery, Medical University of Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria;4. Department of Pathology, Medical University of Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria;5. Department of Orthopedics, Medical University of Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria;6. Department of Radiology, Medical University of Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria;7. Sarcoma Platform Austria, Austria;1. Division of Thoracic Surgery, Owensboro Medical Health System, Owensboro, Kentucky;2. Division of Thoracic Surgery, Greenville Memorial Hospital, Greenville, South Carolina;3. Department of Surgery, Saint Agnes Hospital, Baltimore, Maryland;4. Division of Thoracic Surgery, Baptist Memorial Hospital, Memphis, Tennessee;5. Department of Surgery, Tampa General Hospital, Tampa, Florida;1. Department of Biotechnical and Clinical Laboratory Sciences, State University of New York, Buffalo, NY, USA;2. Department of Neurology, State University of New York, Buffalo, NY, USA;3. Department of Neurology and Center of Clinical Neuroscience, Charles University in Prague, 1st Faculty of Medicine and General University Hospital, Charles University, Prague, Czech Republic;4. Buffalo Neuroimaging Analysis Center, Department of Neurology, State University of New York, Buffalo, NY, USA;5. Department of Pharmaceutical Sciences, State University of New York, Buffalo, NY, USA;6. Department of Radiology, 1st Faculty of Medicine and General University Hospital, Charles University, Prague, Czech Republic;7. IRCCS, S. Maria Nascente, Don Gnocchi Foundation, Milan, Italy |
| |
| Abstract: | ![]()
In the past few years, several targeted therapies have been approved by the U.S. Food and Drug Administration for the treatment of advanced renal cell carcinoma. This has led to an improvement in the progression-free survival and quality of life for these patients. Nevertheless, the use of these and other therapies in the adjuvant setting has failed to demonstrate a clear benefit. Immune therapies and hormonal or targeted therapies have been studied in this indication, and there are clinical trials currently enrolling patients with high risk of relapse. This article reviews the available data and the ongoing trials exploring the role of adjuvant therapy for kidney cancer. |
| |
| Keywords: | Clinical trials Immune therapy Relapse risk Risk reduction Targeted therapy |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
